Opiant Pharmaceuticals reports Q2 EPS (45c), consensus (24c) » 16:5108/0608/06/20
Reports Q2 revenue…
Reports Q2 revenue $6.26M, consensus $6.08M. Commenting on the quarter, Roger Crystal, president and CEO of Opiant, said: "During the past quarter, we made important progress in developing and advancing our lead product candidate, OPNT003 nasal nalmefene, a potential new treatment for opioid overdose, towards NDA filing in 2021, and subsequent potential commercial launch. CDC provisional data for 2019 shows that the opioid epidemic in America is shifting further toward more potent fentanyl and other synthetic opioids, underlying the urgent medical need for a more powerful opioid rescue medication."
|Over a month ago|
Opiant Pharmaceuticals 'disappointed' with court decision in patent case » 15:1406/0706/07/20
The U.S. District Court…
The U.S. District Court for the District of New Jersey has entered a decision in the patent litigation regarding NARCAN Nasal Spray 4mg/spray product. The Court ruled in favor of the Defendants, Teva Pharmaceuticals (TEVA). Opiant's (OPNT) commercial partner Emergent BioSolutions, intends to appeal the decision to the Court of Appeals for the Federal Circuit. "While we are disappointed by the decision today, we are mindful of the important role NARCAN Nasal Spray plays across the United States in helping our communities save lives from opioid overdose," said Roger Crystal, President and Chief Executive Officer of Opiant. "With our pipeline and strong financial position, we remain committed to develop best-in-class medicines for addiction and overdose."
|Over a quarter ago|
Opiant says well positioned with significant cash, no debt » 16:1705/1205/12/20
David O'Toole, CFO…
David O'Toole, CFO of Opiant, said: "We are well-positioned financially with significant cash, no debt and no need to access government programs in the United States or United Kingdom for COVID-19-related financial assistance or relief. Our pipeline investments and overall financial position continue to benefit from a resilient stream of revenue from the sales of Narcan."
Opiant Pharmaceuticals reports Q1 EPS (40c), consensus (18c) » 16:1605/1205/12/20
Reports Q1 revenue $4.3M,…
Reports Q1 revenue $4.3M, consensus $4.85M. As of March 31, Opiant had cash and cash equivalents of $32.2M, compared to approximately $31M at December 31, 2019. The current cash balance does not include the full impact of the NIDA grant of approximately $7.4M or the BARDA contract of approximately $4.6M.
Gritstone Oncology appoints Rahsaan Thompson as general counsel » 08:0504/0604/06/20
Gritstone Oncology (GRTS)…
Gritstone Oncology (GRTS) announced the appointment of Rahsaan Thompson as its executive vice president and general counsel. Prior to Gritstone, Mr. Thompson was the general counsel for Opiant Pharmaceuticals (OPNT), where he was responsible for all legal aspects of corporate strategy, intellectual property, transactions, compliance and regulatory matters.
Opiant Pharmaceuticals reports Q4 EPS 26c versus ($2.49) last year » 16:1303/0403/04/20
Reports Q4 revenue $7.7M,…
Reports Q4 revenue $7.7M, consensus $7.63M. "We continue to make good progress advancing our pipeline, and are excited about our expected 2020 milestones," stated Roger Crystal, M.D., President and Chief Executive Officer of Opiant. "There is a large commercial opportunity for each of our products under development, including the market for opioid reversal agents, which we expect to reach approximately $1 billion in 2022. While access to naloxone is critical to save lives, a substantial need continues to exist for stronger, longer-acting opioid antagonists due to the rapid increase in fentanyl-related overdoses. A new report from the Centers for Disease Control and Prevention showed that fentanyl-related drug overdose deaths in 2018 increased 10 percent from 2017."
Opiant Pharmaceuticals, NCATS form collaboration for OPNT004 development » 08:0201/0201/02/20
Opiant Pharmaceuticals (OPNT) announced that it has signed a Letter of Intent with the National Center for Advancing Translational Sciences to collaborate on the development of OPNT004, a novel cannabinoid receptor antagonist, for the treatment of Acute Cannabinoid Overdose. NCATS is one of 27 divisions and centers of the National Institutes of Health. NCATS will provide development resources around certain pre-clinical activities and studies in order to support Opiant's planned filing of an Investigational New Drug application for OPNT004. This collaboration will be carried out under a Cooperative Research and Development Agreement between Opiant and the NIH. Opiant licensed exclusive global rights for the development and commercialization of drinabant for the emergency treatment of ACO from Sanofi (SNY) in December 2018. The companies subsequently expanded their partnership in July 2019, whereby Sanofi will be responsible for manufacturing OPNT004.
Fly Intel: After Hours Movers » 18:4411/1211/12/19
CDLX, TWOU, OPNT, DDOG, PTE, ADPT, ADT, BDSI, AQMS, YY, HUYA, RUN, VRAY, DZSI, HIIQ, CBPX, KNSL, BOXL, SSTI, TVTY, GEVO, CSIQ, SDC, SWKS, VREX, TLRY, NXTC, HALO, CYBR, I
UP AFTER EARNINGS: …
UP AFTER EARNINGS: Cardlytics (CDLX) up 24.2%... 2U (TWOU) up 14.5%... Opiant Pharma (OPNT) up 13.7%... DataDog (DDOG) up 13.3%... Polarity (PTE) up 8.3%... Adaptive Biotech (ADPT) up 5.8%... ADT Inc (ADT) up 5.8%... BioDelivery Sciences (BDSI) up 5.0%... Aqua Metals (AQMS) up 4.8%... YY (YY) up 4.0%... Huya (HUYA) up 3.9%... SunRun (RUN) up 2.9%... ViewRay (VRAY) up 2.8%... DASAN Zhone Solutions (DZSI) up 2.4%... Health Insurance Innovations (HIIQ) up 2.1%... Continental Building (CBPX) up 1.5%. ALSO HIGHER: Kinsale Capital (KNSL) up 8.2% after entering S&P SmallCap 600 index. DOWN AFTER EARNINGS: Boxlight (BOXL) down 15.3%... ShotSpotter (SSTI) down 12.1%... Tivity Health (TVTY) down 11.9%... Gevo (GEVO) down 9.8%... Canadian Solar (CSIQ) down 9.5%... SmileDirectClub (SDC) down 7.3%... Skyworks (SWKS) down 5.2%... Varex Imaging (VREX) down 3.6%... Tilray (TLRY) down 2.2%. ALSO LOWER: NextCure (NXTC) down 8.9% after equity offering... Halozyme (HALO) down 4.9% after convertible debt offering... CyberArk Software (CYBR) down 3.0% after convertible debt offering... Intelsat (I) down 2.9% after being downgraded to Neutral at JPMorgan. Movers as of 18:15ET.
Opiant Pharmaceuticals reports Q3 EPS $1.97, consensus (9c) » 16:2911/1211/12/19
Reports Q3 revenue…
Reports Q3 revenue $20.6M, consensus $5.52M. David O'Toole, CFO, says, "I am extremely pleased to report that, based on net sales of NARCAN Nasal Spray exceeding $200 million through the third quarter of 2019, we have earned a one-time $13.5 million milestone. After certain required deductions, the net milestone payment of $10.8 million will further fortify our already strong balance sheet, and we now expect a cash balance of $28 million to $30 million at the end of 2019, versus our prior projection of $17 million to $20 million."
Dawson James to hold a conference » 04:5510/2910/29/19
AIM, ARTL, ATOS, AZRX, BCDA, BCLI, BYSI, CANF, CLBS, CLSN, CTXR, CVM, DMPI, FBIO, HOTH, IDXG, KOOL, LCTX, MESO, OPNT, ORGS, SPHS, TNXP, URG, VNRX, ZYNE
2019 Annual Small Cap…
2019 Annual Small Cap Growth Stock Conference will be held in Jupiter, FL on October 28-29.